News

Adelaide, Australia, 30th June 2020 – Australian biotechnology company GPN Vaccines, which is developing a vaccine against the world’s foremost bacterial pathogen, Streptococcus pneumoniae, is pleased to announce it has raised A$7 million (USD$4.9 million) in an oversubscribed Series A2 investment round. GPN Vaccines has created...

Adelaide, Australia, 25 May 2020 – GPN Vaccines is pleased to announce Dr Ismail Kola has joined the Company’s Board of Directors. Dr Kola is a Senior Partner at Forepont Capital, a New York-based venture capital firm investing in pharmaceutical and biotechnology companies that improve healthcare outcomes....

Adelaide, Australia, 7 April 2020 – GPN Vaccines is pleased to announce the appointment of Dr Paul Wabnitz as the Company's Medical Director and Mr Jim Ackland as Director, Regulatory & Quality. These two appointments will significantly strengthen the clinical development team in preparation for...

Protecting children and adults from the world’s foremost bacterial pathogen